跳至主要内容
临床试验/CTRI/2022/11/047577
CTRI/2022/11/047577已完成未知

A Prospective, Randomized, Double-Blind, Placebo Controlled Clinical Study to Evaluate the Effects of KSM-66 Ashwagandha® capsule (300 mg) on Skin and Hair Health in Healthy Men and Women

Ixoreal Biomed0 个研究点目标入组 92 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
92

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Healthy adult men and women participants more than equal to 18 years and less than equal to 60 years of age.
  • 2.Willingness to follow the protocol requirements as evidenced by written
  • informed consent.
  • 3.Participants who were on consistent dietary, hair and skin product 3 months
  • prior to start of the study and are willing to follow the same during the study.
  • 4.Participants who agree not to use any medication (prescription and over the
  • counter), including vitamins and minerals, during or before the course of this
  • 5.Participants with mild to moderate hair loss.
  • 6.Willing to come for all follow-up visits.
  • 7.Participants who agree not to cut hair for the entire duration of the study.
  • 8.Participants willing to undergo Trichoscan evaluation and not to wash their hair
  • 48 hours before the visit.
  • 9.Participants willing to take proper contraceptives during the study and period.
  • 10.Participants or LAR are able to and willing to give meaningful, written
  • informed consent prior to participation in the trial, in accordance with
  • regulatory requirements.
  • 11.Participants who agree to take investigational product (i.e., Till Day 75 ± 4).

排除标准

  • 1.Participants having any clinically significant medical history, medical finding including rosacea, eczema, psoriasis, and atopic dermatitis or an on-going medical or psychiatric condition exists which in the opinion of the
  • Investigator could jeopardize the safety of the subject, impact validity of the study results or interfere with the completion of study according to the protocol.
  • 2.Participants on any medication or supplement for hair loss, including finasteride, any other 5 alpha-reductase inhibitor, minoxidil, steroids, or hormonal products, during the 3 months prior to study commencement.
  • 3.Participants having a history of hypersensitivity reactions (i.e., allergic or oversensitivity to study medication).
  • 4.Participants who have undergone or plan to undergo hair transplantation surgery during the study period.
  • 5.Participants with facial skin cancer.
  • 6.Participants with sunburn, moderate to pronounced suntan, uneven skin tones, tattoos, scars or other disfiguration, dilated vessels or other conditions on the test area that might influence the test results.
  • 7.Participants with severe seborrheic dermatitis, alopecic disease, except for androgenic alopecia, and scalp disorders, such as scalp psoriasis and infection.
  • 8.Participants who have participated in a clinical study during the preceding 180 days.
  • 9.Participants having eating disorders (i.e., bulimia, psychogenic eating disorders, etc.).
  • 10.Pregnant and lactating females.
  • 11.Participants with alcohol addiction or persistent abuse of drugs of dependence.

研究者

发起方
Ixoreal Biomed

相似试验